Clinical Trials Logo

Hypercalciuria clinical trials

View clinical trials related to Hypercalciuria.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03325114 Terminated - Clinical trials for Type 1 Diabetes Mellitus

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

Start date: June 28, 2019
Phase: Phase 2
Study type: Interventional

This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes

NCT ID: NCT01928082 Terminated - Osteoporosis Clinical Trials

The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

Start date: August 1, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement in women with familial hypercalciuria compared to nonfamilial hypercalciuria.

NCT ID: NCT01426165 Terminated - Clinical trials for Primary Hypomagnesemia (Disorder)

Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients

Start date: April 2011
Phase: N/A
Study type: Interventional

Hypomagnesemia (low magnesium) is an electrolyte imbalance commonly found in up to 65% of critically ill patients. Possible consequences of hypomagnesemia include neuromuscular and neurologic dysfunction, heart arrhythmias, and alterations in other electrolytes. Data has shown that critically ill patients with hypomagnesemia have a significantly higher mortality rate than patients with a normal magnesium level. The most simple and commonly used test to diagnose hypomagnesemia is a serum magnesium level. Based on the magnesium level and symptoms of hypomagnesemia, patients may be replaced with either oral or intravenous (IV) magnesium. When replacing magnesium via the IV route, approximately half of the dose is retained by the body while the remainder is excreted in the urine. The low retention rate is due to the slow uptake of magnesium by cells and decreased magnesium reabsorption by the kidneys in response to the delivery of a large concentration of magnesium. The purpose of this study is to determine whether an eight hour compared to a four hour infusion of IV magnesium sulfate results in a greater retention of the magnesium dose.